Base de dados : MEDLINE
Pesquisa : D03.633.100.834 [Categoria DeCS]
Referências encontradas : 2363 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 237 ir para página                         

  1 / 2363 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29184947
[Au] Autor:Park E; Cheon CH
[Ad] Endereço:Department of Chemistry, Korea University, 145 Anam-ro, Seongbuk-gu, Seoul 02841, Republic of Korea. cheon@korea.ac.kr.
[Ti] Título:A general strategy for the synthesis of indoloquinolizine alkaloids via a cyanide-catalyzed imino-Stetter reaction.
[So] Source:Org Biomol Chem;15(48):10265-10275, 2017 Dec 13.
[Is] ISSN:1477-0539
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:A new strategy applicable to the synthesis of indoloquinolizine natural products has been developed. A cyanide-catalyzed intramolecular imino-Stetter reaction of aldimines, derived from 2-aminocinnamic acid derivatives and 2-pyridinecarboxaldehydes, provided indole-3-acetic acid derivatives bearing a pyridyl ring at the 2-position. Reduction of the carboxylic acid moiety to an alcohol followed by activation of the resulting alcohol with Tf O or TsCl generated indoloquinolizinium salts, which were utilized as precursors for indoloquinolizine natural products. The advantage of this protocol was successfully demonstrated in the total syntheses of arborescidine A and nauclefidine.
[Mh] Termos MeSH primário: Alcaloides/síntese química
Cianetos/química
Iminas/química
Quinolizinas/síntese química
[Mh] Termos MeSH secundário: Alcaloides/química
Catálise
Estrutura Molecular
Quinolizinas/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkaloids); 0 (Cyanides); 0 (Imines); 0 (Quinolizines)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1039/c7ob02691a


  2 / 2363 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27773936
[Au] Autor:Liu Y; Qi Y; Bai ZH; Ni CX; Ren QH; Xu WH; Xu J; Hu HG; Qiu L; Li JZ; He ZG; Zhang JP
[Ad] Endereço:Department of Pharmacy, Shanghai East Hospital, Tongji University, Shanghai 310000, China.
[Ti] Título:A novel matrine derivate inhibits differentiated human hepatoma cells and hepatic cancer stem-like cells by suppressing PI3K/AKT signaling pathways.
[So] Source:Acta Pharmacol Sin;38(1):120-132, 2017 Jan.
[Is] ISSN:1745-7254
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Matrine is an alkaloid extracted from a Chinese herb Sophora flavescens Ait, which has shown chemopreventive potential against various cancers. In this study, we evaluated the anticancer efficacy of a novel derivative of matrine, (6aS, 10S, 11aR, 11bR, 11cS)-10- methylamino-dodecahydro- 3a,7a-diazabenzo (de) (MASM), against human hepatocellular carcinoma (HCC) cells and their corresponding sphere cells in vitro and in vivo. Human HCC cell lines (Hep3B and Huh7) were treated with MASM. Cell proliferation was assessed using CCK8 and colony assays; cell apoptosis and cell cycle distributions were examined with flow cytometry. The expression of cell markers and signaling molecules was detected using Western blot and qRT-PCR analyses. A sphere culture technique was used to enrich cancer stem cells (CSC) in Hep3B and Huh7 cells. The in vivo antitumor efficacy of MASM was evaluated in Huh7 cell xenograft model in BALB/c nude mice, which were administered MASM (10 mg·kg ·d , ig) for 3 weeks. After the treatment was completed, tumor were excised and weighed. A portion of tumor tissue was enzymatically dissociated to obtain a single cell suspension for the spheroid formation assays. MASM (2, 10, 20 µmol/L) dose-dependently inhibited the proliferation of HCC cells, and induced apoptosis, which correlated with a reduction in Bcl-2 expression and an increase in PARP cleavage. MASM also induced cell cycle arrest in G /G phase, which was accompanied by increased p27 and decreased Cyclin D1 expression. Interestingly, MASM (2, 10, and 20 µmol/L) drastically reduced the EpCAM /CD133 cell numbers, suppressed the sphere formation, inhibited the expression of stem cell marker genes and promoted the expression of mature hepatocyte markers in the Hep3B and Huh7 spheroids. Additionally, MASM dose-dependently suppressed the PI3K/AKT/mTOR and AKT/GSK3ß/ß-catenin signaling pathways in Hep3B and Huh7 cells. In Huh7 xenograft bearing nude mice, MASM administration significantly inhibited Huh7 xenograft tumor growth and markedly reduced the number of surviving cancer stem-like cells in the tumors. MASM administration also reduced the expression of stem cell markers while increasing the expression of mature hepatocyte markers in the tumor tissues. The novel derivative of matrine, MASM, markedly suppresses HCC tumor growth through multiple mechanisms, and it may be a promising candidate drug for the treatment of hepatocellular carcinoma.
[Mh] Termos MeSH primário: Alcaloides/química
Alcaloides/farmacologia
Carcinoma Hepatocelular/patologia
Proliferação Celular/efeitos dos fármacos
Compostos Heterocíclicos de 4 ou mais Anéis/farmacologia
Neoplasias Hepáticas/patologia
Células-Tronco Neoplásicas/efeitos dos fármacos
Quinolizinas/química
Quinolizinas/farmacologia
Transdução de Sinais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacologia
Apoptose/efeitos dos fármacos
Contagem de Células
Pontos de Checagem do Ciclo Celular/efeitos dos fármacos
Diferenciação Celular
Linhagem Celular Tumoral
Ciclina D1/biossíntese
Relação Dose-Resposta a Droga
Molécula de Adesão da Célula Epitelial/metabolismo
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Camundongos
Camundongos Nus
Células-Tronco Neoplásicas/enzimologia
Células-Tronco Neoplásicas/metabolismo
Fosfatidilinositol 3-Quinases
Antígeno Nuclear de Célula em Proliferação/biossíntese
Proteínas Proto-Oncogênicas c-bcl-2/metabolismo
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (10-methylaminododecahydro-3a,7a-diazabenzo(de)anthracene-8-thione); 0 (Alkaloids); 0 (Antineoplastic Agents); 0 (EPCAM protein, human); 0 (Epithelial Cell Adhesion Molecule); 0 (Heterocyclic Compounds, 4 or More Rings); 0 (Proliferating Cell Nuclear Antigen); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (Quinolizines); 0 (p27 antigen); 136601-57-5 (Cyclin D1); EC 2.7.1.- (Phosphatidylinositol 3-Kinases); N390W430AC (matrine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180101
[Lr] Data última revisão:
180101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE
[do] DOI:10.1038/aps.2016.104


  3 / 2363 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27778062
[Au] Autor:Tutka P; Kondrat-Wróbel MW; Zaluska K; Zólkowska D; Florek-Luszczki M; Luszczki JJ
[Ad] Endereço:Department of Pharmacology, University of Rzeszów, Al. Rejtana 16c, 35-959, Rzeszów, Poland. tutka@umlub.pl.
[Ti] Título:Cytisine inhibits the protective activity of various classical and novel antiepileptic drugs against 6 Hz-induced psychomotor seizures in mice.
[So] Source:Psychopharmacology (Berl);234(2):281-291, 2017 Jan.
[Is] ISSN:1432-2072
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cytisine (CYT) is a partial agonist of brain α4ß2 nicotinic acetylcholine receptors widely used in Central/Eastern Europe for smoking cessation. OBJECTIVES: This study evaluated the effect of CYT on the ability of classical and novel antiepileptic drugs to prevent seizures evoked by the 6-Hz test, a model of psychomotor seizures in mice thought as a model of drug-resistant seizures. RESULTS: CYT administered intraperitoneally (i.p.) in a dose of 2 mg kg significantly inhibited the anticonvulsant activity of lacosamide, levetiracetam, and pregabalin, increasing their median effective doses 50 (ED ) values from 6.88 to 10.52 mg kg (P < 0.05) for lacosamide, from 22.08 to 38.26 mg kg (P < 0.05) for levetiracetam, and from 40.48 to 64.61 mg kg (P < 0.01) for pregabalin, respectively. There were no significant changes in total brain concentrations of lacosamide, levetiracetam, and pregabalin following CYT i.p. administration. CYT administered in a dose of 2 mg kg failed to change the protective action of clobazam, clonazepam, phenobarbital, tiagabine, and valproate in the 6-Hz test. Neither CYT (2 mg kg ) alone nor its combination with the anticonvulsant drugs (at their ED values from the 6-Hz test) affected motor coordination; skeletal muscular strength and long-term memory, as determined in the chimney; and grip strength and passive avoidance tests, respectively. CONCLUSION: CYT-evoked alterations in the protection provided by some antiepileptic drugs against seizures can be of serious concern for epileptic smokers, who might demonstrate therapeutic failure to lacosamide, levetiracetam, and pregabalin, resulting in possible breakthrough seizure attacks.
[Mh] Termos MeSH primário: Alcaloides/toxicidade
Anticonvulsivantes/uso terapêutico
Eletrochoque/efeitos adversos
Agonistas Nicotínicos/toxicidade
Convulsões/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Anticonvulsivantes/farmacologia
Azocinas/toxicidade
Relação Dose-Resposta a Droga
Masculino
Memória de Longo Prazo/efeitos dos fármacos
Memória de Longo Prazo/fisiologia
Camundongos
Fenobarbital/antagonistas & inibidores
Fenobarbital/farmacologia
Fenobarbital/uso terapêutico
Piracetam/análogos & derivados
Piracetam/antagonistas & inibidores
Piracetam/farmacologia
Piracetam/uso terapêutico
Quinolizinas/toxicidade
Convulsões/etiologia
Convulsões/psicologia
Ácido Valproico/antagonistas & inibidores
Ácido Valproico/farmacologia
Ácido Valproico/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkaloids); 0 (Anticonvulsants); 0 (Azocines); 0 (Nicotinic Agonists); 0 (Quinolizines); 230447L0GL (etiracetam); 53S5U404NU (cytisine); 614OI1Z5WI (Valproic Acid); YQE403BP4D (Phenobarbital); ZH516LNZ10 (Piracetam)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE
[do] DOI:10.1007/s00213-016-4461-0


  4 / 2363 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28946137
[Au] Autor:Zhang YY; Yi M; Huang YP
[Ad] Endereço:Department of Pharmacology, Guizhou Medical University, Guizhou, China.
[Ti] Título:Oxymatrine Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats.
[So] Source:Cell Physiol Biochem;43(2):626-635, 2017.
[Is] ISSN:1421-9778
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIMS: Doxorubicin-induced cardiac toxicity has been a major concern of oncologists and is considered the main restriction on its clinical application. Oxymatrine has shown potent anti-cancer, anti-fibrosis, and anti-oxidative effects. Recently, it has been reported that oxymatrine is protective against some cardiovascular diseases. In this study, we aimed to investigate the effects of oxymatrine on doxorubicin-induced cardiotoxicity in rat hearts and H9c2 cells. METHODS: Creatine Kinase - MB (CK-MB) and Lactate Dehydrogenase (LDH) levels were determined using commercial kits. Biochemical indices reflecting oxidative stress, such as catalase (CAT), malonyldialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) were also analyzed with commercial kits. Mitochondrial reactive oxygen species (ROS) 2',7'-dichlorofluorescin diacetate (DCFH-DA) was measured by fluorescence microscopy. Histological analyses were conducted to observe morphological changes, and apoptosis was measured using a commercial kit. Western blots were used to detect the level of expression of cleaved caspase-3. RESULTS: Doxorubicin treatment significantly increased oxidative stress levels, as indicated by catalase, malonyldialdehyde, superoxide dismutase, glutathione peroxidase and reactive oxygen species. Doxorubicin also increased pathological damage in myocardial tissue, myocardial ROS levels, and malonyldialdehyde levels, and induced apoptosis in myocardial tissues and H9c2 cells. All of these doxorubicin-induced effects were attenuated by oxymatrine. CONCLUSION: These in vitro and in vivo findings indicate that oxymatrine may be a promising cardioprotective agent against doxorubicin-induced cardiotoxicity, at least in part mediated through oxymatrine's inhibition of cardiac apoptosis and oxidative stress.
[Mh] Termos MeSH primário: Alcaloides/uso terapêutico
Antibióticos Antineoplásicos/efeitos adversos
Cardiotônicos/uso terapêutico
Cardiotoxicidade/tratamento farmacológico
Doxorrubicina/efeitos adversos
Quinolizinas/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Apoptose/efeitos dos fármacos
Cardiotoxicidade/metabolismo
Cardiotoxicidade/patologia
Linhagem Celular
Coração/efeitos dos fármacos
Masculino
Miocárdio/metabolismo
Miocárdio/patologia
Estresse Oxidativo/efeitos dos fármacos
Ratos
Ratos Sprague-Dawley
Espécies Reativas de Oxigênio/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkaloids); 0 (Antibiotics, Antineoplastic); 0 (Cardiotonic Agents); 0 (Quinolizines); 0 (Reactive Oxygen Species); 80168379AG (Doxorubicin); 85U4C366QS (oxymatrine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170926
[St] Status:MEDLINE
[do] DOI:10.1159/000480471


  5 / 2363 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28738241
[Au] Autor:Tang Y; Xiong J; Zou Y; Wang W; Huang C; Zhang HY; Hu JF
[Ad] Endereço:Department of Natural Products Chemistry, School of Pharmacy, Fudan University, No. 826 Zhangheng Road, Shanghai, 201203, PR China.
[Ti] Título:Annotinolide F and lycoannotines A-I, further Lycopodium alkaloids from Lycopodium annotinum.
[So] Source:Phytochemistry;143:1-11, 2017 Nov.
[Is] ISSN:1873-3700
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Seven lycopodine-type (annotinolide F and lycoannotines A-F), two lycodine-type (lycoannotines G and H), and one fawcettimine-type (lycoannotine I) previously undescribed naturally occurring Lycopodium alkaloids together with thirteen known ones were isolated from the whole plant of Lycopodium annotinum. Their structures and absolute configurations were determined by extensive spectroscopic methods, single-crystal X-ray diffraction, chemical transformation, and electronic circular dichroism (ECD) calculations. Among the isolates, annotinolide F, lycoannotines A and B are unusual 7,8-seco-lycopodane derivatives, and annotinolide F even further possesses a rare 8,5-lactone framework through a lactonization after the C-7/C-8 bond cleavage. Lycoannotine C is an uncommon 8,15-seco lycopodine-type alkaloid, whereas lycoannotine I represents the first example of a naturally occurring C-9/N bond cleavage product of fawcettimine-type alkaloid. Among them, only lycoannotine I was found to show considerable anti-butyrylcholinesterase (anti-BuChE) activity.
[Mh] Termos MeSH primário: Alcaloides/isolamento & purificação
Inibidores da Colinesterase/isolamento & purificação
Lycopodium/química
[Mh] Termos MeSH secundário: Alcaloides/química
Alcaloides/farmacologia
Inibidores da Colinesterase/química
Inibidores da Colinesterase/farmacologia
Cristalografia por Raios X
Estrutura Molecular
Quinolizinas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkaloids); 0 (Cholinesterase Inhibitors); 0 (Quinolizines); 0 (fawcettimine); 2P5MU968XW (lycopodine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171002
[Lr] Data última revisão:
171002
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170725
[St] Status:MEDLINE


  6 / 2363 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28652742
[Au] Autor:Xu X; Wang Y; Wu J; Hu X; Zhu H; Zhang X; Wang Y; Gui L; Zhao M; Peng S
[Ad] Endereço:Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Engineering Research Center of Endogenous Prophylactic of Ministry of Education of China, Beijing Laboratory of Biomedical Materials, College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of Chin
[Ti] Título:ATIQCTPC: a nanomedicine capable of targeting tumor and blocking thrombosis in vivo.
[So] Source:Int J Nanomedicine;12:4415-4431, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:To overcome the harmful side effects, low tolerance, and undesirable outcomes of the anticancer drugs, we used ethane-1,2-diamine to bridge antitumoral ( )-3-acetyl-4-oxo-tetrahydroindolo[2,3-a]quinolizine-6-carboxylic acid (ATIQC) and tumor-targeting d-glucuronic acid, thereby providing (6 )-3-acetyl-4-oxo- -(2-(3,4,5,6-tetrahydroxytetrahydro-2H-pyran-2-carboxamido)ethyl)-4,6,7,12-tetrahydroindolo[2,3-a]quinolizine-6-carboxamide (ATIQCTPC). Atomic force microscopy images visualized, that in serum, ATIQCTPC formed particles of height <81 nm. These particles effectively avoided phagocytosis of macrophages and were stable in blood circulation. Distribution analysis indicated that ATIQCTPC accumulated and released ATIQC in the tumor tissue through a targeting manner. Thus, the antitumor and the anti-thrombotic activities of ATIQCTPC were 100-fold higher than those of ATIQC, and ATIQCTPC was able to prevent cancer patients from suffering from thrombosis. Based on the observation that ATIQCTPC decreased serum tumor necrosis factor-α (TNF-α) and interleukin-8 (IL-8) in S180 mice, we hypothesized that this is the mechanism that ATIQCTPC utilized to slow tumor growth. Additionally, we observed that ATIQCTPC inhibited thrombosis by decreasing serum P-selectin of thrombotic rats. The intermolecular association and the hexamerization manner of ATIQCTPC were experimentally evidenced and correlated with the formation of the nanoparticles.
[Mh] Termos MeSH primário: Antineoplásicos/química
Antineoplásicos/farmacologia
Indóis/farmacologia
Nanopartículas/administração & dosagem
Quinolizinas/farmacologia
Trombose/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/administração & dosagem
Sistemas de Liberação de Medicamentos/métodos
Ácido Glucurônico/administração & dosagem
Ácido Glucurônico/química
Ácido Glucurônico/farmacologia
Indóis/química
Interleucina-8/metabolismo
Macrófagos/efeitos dos fármacos
Masculino
Camundongos
Camundongos Endogâmicos ICR
Microscopia de Força Atômica
Nanopartículas/química
Neoplasias Experimentais/tratamento farmacológico
Selectina-P/antagonistas & inibidores
Selectina-P/metabolismo
Fagocitose/efeitos dos fármacos
Quinolizinas/química
Ratos Sprague-Dawley
Ratos Wistar
Distribuição Tecidual
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (ATIQCTPC compound); 0 (Antineoplastic Agents); 0 (Indoles); 0 (Interleukin-8); 0 (P-Selectin); 0 (Quinolizines); 0 (Tumor Necrosis Factor-alpha); 8A5D83Q4RW (Glucuronic Acid)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S129989


  7 / 2363 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28499934
[Au] Autor:Liu SQ; Zhang ML; Zhang HJ; Liu FZ; Chu RJ; Zhang GX; Zhu L
[Ad] Endereço:Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China.
[Ti] Título:Matrine promotes oligodendrocyte development in CNS autoimmunity through the PI3K/Akt signaling pathway.
[So] Source:Life Sci;180:36-41, 2017 Jul 01.
[Is] ISSN:1879-0631
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:AIMS: Matrine (MAT), a quinolizidine alkaloid derived from the herb Radix Sophorae flavescens, has been recently found to be beneficial in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, mainly through its anti-inflammatory effect. In the present study, we tested the effect of MAT on ongoing EAE and defined possible mechanisms underlying its effects on myelination and oligodendrocytes. MAIN METHODS: EAE was induced in C57BL/6 mice and MAT treatment was started at disease onset. Clinical scores were monitored daily; spinal cords and the corpus callosum brain region of mice were harvested on day 23 p.i. for inflammatory infiltration and demyelination of the central nervous system. Myelin content and the development of oligodendrocytes and their precursors were determined by immunostaining, and expression of p-Akt, p-mTOR, p-PI3K, and p-P70S6 was determined by Western blot. KEY FINDINGS: MAT effectively suppressed EAE severity and increased the expression of proteolipid protein, a myelin protein that is a marker of CNS myelin. MAT treatment largely increased the number of mature oligodendrocytes, and significantly activated the PI3K/Akt/mTOR signaling pathway, which is required for oligodendrocyte survival and axon myelination. SIGNIFICANCE: These findings demonstrate a beneficial effect of MAT on oligodendrocyte differentiation and myelination during EAE, most likely through activating the PI3K/Akt/mTOR signaling pathway.
[Mh] Termos MeSH primário: Alcaloides/farmacologia
Encefalomielite Autoimune Experimental/tratamento farmacológico
Esclerose Múltipla/tratamento farmacológico
Oligodendroglia/efeitos dos fármacos
Quinolizinas/farmacologia
[Mh] Termos MeSH secundário: Alcaloides/isolamento & purificação
Animais
Autoimunidade/efeitos dos fármacos
Diferenciação Celular/efeitos dos fármacos
Corpo Caloso/efeitos dos fármacos
Corpo Caloso/patologia
Modelos Animais de Doenças
Encefalomielite Autoimune Experimental/patologia
Feminino
Camundongos
Camundongos Endogâmicos C57BL
Esclerose Múltipla/patologia
Bainha de Mielina/metabolismo
Oligodendroglia/metabolismo
Fosfatidilinositol 3-Quinase/metabolismo
Proteínas Proto-Oncogênicas c-akt/metabolismo
Quinolizinas/isolamento & purificação
Índice de Gravidade de Doença
Transdução de Sinais/efeitos dos fármacos
Sophora/química
Serina-Treonina Quinases TOR/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkaloids); 0 (Quinolizines); EC 2.7.1.1 (TOR Serine-Threonine Kinases); EC 2.7.1.137 (Phosphatidylinositol 3-Kinase); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); N390W430AC (matrine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170629
[Lr] Data última revisão:
170629
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170514
[St] Status:MEDLINE


  8 / 2363 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28382770
[Au] Autor:Wang X; Lin H; Zhang R
[Ad] Endereço:Shenzhen Bao'an Traditional Chinese Medicine Hospital Group, the Affiliated Hospital of Guangzhou University of Chinese Medicine, Shenzhen, 518133, China.
[Ti] Título:The Clinical Efficacy and Adverse Effects of Interferon Combined with Matrine in Chronic hepatitis B: A Systematic Review and Meta-Analysis.
[So] Source:Phytother Res;31(6):849-857, 2017 Jun.
[Is] ISSN:1099-1573
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Currently, many studies have demonstrated certain beneficial effects of interferon (IFN) combined with matrine (Mat) for chronic hepatitis B (CHB) in China. However, the evidence from these randomized control trials is still controversial. Therefore, the aim of this meta-analysis was to explore the efficacy and safety of Mat combined with IFN for CHB. We performed a systematic search of seven databases to identify all randomized controlled trials that treated CHB with IFN or IFN plus Mat from their start date to September 30, 2015. The clinical efficacy and adverse effects were evaluated. Nine studies involving 1089 participants were included. Compared with IFN monotherapy, IFN 5 MU combined with Mat 150 mg augmented the hepatitis B e-antigen negative conversion rate after 3-month treatment [relative ratio (RR) = 1.41; 95% confidence interval (CI) (1.18, 1.69), p = 0.0002] and after 12-month treatment [RR = 1.96; 95% CI (1.21, 3.19), p = 0.006], hepatitis B virus DNA negative conversion rate after 3-month treatment [RR = 1.37; 95% CI (1.16, 1.62), p = 0.0002] and after 12-month treatment [RR = 1.96; 95% CI (1.21, 3.19), p = 0.006], hepatitis B virus e antibody (anti-HBe) conversion rate after 3-month treatment [RR = 1.47; 95% CI (1.19, 1.81), p = 0.0003], and AST level after 3-week treatment [weighted mean difference = -22; 95% CI (-40.41, -3.59), p = 0.02]. Furthermore, IFN 3 MU 3 months combined with Mat 150 mg after 2-month treatment reduced the risk of leucopenia and thrombocytopenia [RR = 0.55; 95% CI (0.36, 0.85), p = 0.007]. Unfortunately, all of the included trials were not in favor of hepatitis B surface antigen (HBsAg) negative conversion rate or influenza-like symptoms. Combination therapy with IFN plus Mat exhibited better clinical efficacy and fewer adverse effects than did IFN monotherapy in patients with CHB, except in the improvement of HBsAg negative conversion rate and influenza-like symptoms. Given the poor methodological quality of the evidence currently available, future high-quality, three-blinded randomized control trials are necessary to confirm these results. Copyright © 2017 John Wiley & Sons, Ltd.
[Mh] Termos MeSH primário: Alcaloides/efeitos adversos
Alcaloides/uso terapêutico
Hepatite B Crônica/tratamento farmacológico
Interferon-alfa/efeitos adversos
Interferon-alfa/uso terapêutico
Quinolizinas/efeitos adversos
Quinolizinas/uso terapêutico
[Mh] Termos MeSH secundário: Antivirais/efeitos adversos
Antivirais/uso terapêutico
China
Quimioterapia Combinada
Seres Humanos
Ensaios Clínicos Controlados Aleatórios como Assunto
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Alkaloids); 0 (Antiviral Agents); 0 (Interferon-alpha); 0 (Quinolizines); N390W430AC (matrine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170407
[St] Status:MEDLINE
[do] DOI:10.1002/ptr.5808


  9 / 2363 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28373137
[Au] Autor:Liu Z; Zhang Y; Tang Z; Xu J; Ma M; Pan S; Qiu C; Guan G; Wang J
[Ad] Endereço:Department of Cardiology, Shaanxi Provincial People's Hospital, Xi'an 710000, China; Institute of Molecular Genetics, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710000, China. Electronic address: liuzhongwei@xjtu.edu.cn.
[Ti] Título:Matrine attenuates cardiac fibrosis by affecting ATF6 signaling pathway in diabetic cardiomyopathy.
[So] Source:Eur J Pharmacol;804:21-30, 2017 Jun 05.
[Is] ISSN:1879-0712
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Cardiac function and compliance impairments are the features of cardiac fibrosis. Matrine shows therapeutic effects on cardiovascular diseases and organ fibrosis. In this study, we examined the therapeutic effects and mechanisms of matrine on cardiac fibrosis of DbCM. Matrine was administrated orally to rats with DbCM. Cardiac functions and compliance were evaluated. The collagen deposition was visualized by sirius red staining. Real-time PCR was used to determine the expression level of miRNA. Western blotting was performed to assess the protein expression. NFAT nuclear translocation was evaluated by fluorescent immunochemistry staining and Western blotting. Intracellular calcium level was assessed by fura-2/AM staining. A colorimetric method was used to determine calcineurin enzymatic activity. Impaired cardiac function and compliance were observed in rats with DbCM. Increased collagen deposition in cardiac tissue was found. Furthermore, ATF6 signaling was activated, leading to intracellular calcium accumulation and NFAT activation which further initiated ECM gene expressions. Matrine administration recovered cardiac function and improved compliance by exerting inhibitory effects against ATF6 signaling- induced fibrosis. The high- glucose incubation induced ATF6 signaling activation in cultured CFs to increase the synthesis of ECM. Matrine blocked the ATF6 signaling in CFs to inhibit ECM synthesis within non- cytotoxic concentrations. ATF6 signaling induced cardiac fibrosis was one of the mechanisms involved in DbCM, which was characterized by loss of cardiac compliance and functions. Matrine attenuated cardiac compliance and improved left ventricular functions by exerting therapeutic effects against cardiac fibrosis via affecting ATF6 signaling pathway.
[Mh] Termos MeSH primário: Fator 6 Ativador da Transcrição/metabolismo
Alcaloides/farmacologia
Cardiomiopatias Diabéticas/tratamento farmacológico
Cardiomiopatias Diabéticas/patologia
Miocárdio/patologia
Quinolizinas/farmacologia
Transdução de Sinais/efeitos dos fármacos
[Mh] Termos MeSH secundário: Alcaloides/uso terapêutico
Animais
Calreticulina/metabolismo
Proliferação Celular/efeitos dos fármacos
Cardiomiopatias Diabéticas/metabolismo
Cardiomiopatias Diabéticas/fisiopatologia
Diástole/efeitos dos fármacos
Relação Dose-Resposta a Droga
Estresse do Retículo Endoplasmático/efeitos dos fármacos
Matriz Extracelular/efeitos dos fármacos
Matriz Extracelular/metabolismo
Fibrose
Glucose/farmacologia
Masculino
Fatores de Transcrição NFATC/metabolismo
Quinolizinas/uso terapêutico
Ratos
Ratos Sprague-Dawley
Sístole/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Activating Transcription Factor 6); 0 (Alkaloids); 0 (Atf6 protein, rat); 0 (Calreticulin); 0 (NFATC Transcription Factors); 0 (Quinolizines); IY9XDZ35W2 (Glucose); N390W430AC (matrine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE


  10 / 2363 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28368325
[Au] Autor:Zhang J; Wang Y; Zheng W
[Ad] Endereço:Department of Oncology, Henan Academy institute of Traditional Chinese Medicine, Zhengzhou 450000, Henan, China. zhangjunping888@163.com.
[Ti] Título:Development of a Novel Electrochemical Sensor for Determination of Matrine in Sophora flavescens.
[So] Source:Molecules;22(4), 2017 Apr 01.
[Is] ISSN:1420-3049
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:A simple and sensitive electrochemical sensor fabricated with graphene nanosheets (GNs) and a hydroxyapatite (HA) nanocomposite-modified glassy carbon electrode (GCE) was developed for the determination of matrine (MT). The as-prepared electrode (GNs/HA/GCE) was verified to outperform bare a GCE and GNs-modified electrode with increased oxidation peak currents and the decreased over-potential in the redox process of MT, indicating the great enhancement of electrocatalytic activity toward the oxidation of MT by the composite of GNs and HA. Under the optimized conditions, the oxidation peak currents were related linearly with the concentration of MT, ranging from 2 µM to 3 mM, and the detection limit (S/N = 3) was 1.2 µM. In addition, the proposed electrochemical sensor can be successfully applied in the quantitative determination of MT in extract.
[Mh] Termos MeSH primário: Alcaloides/análise
Técnicas Biossensoriais
Técnicas Eletroquímicas
Quinolizinas/análise
Sophora/química
[Mh] Termos MeSH secundário: Grafite
Nanocompostos/química
Nanocompostos/ultraestrutura
Oxirredução
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Alkaloids); 0 (Quinolizines); 7782-42-5 (Graphite); N390W430AC (matrine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170531
[Lr] Data última revisão:
170531
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE



página 1 de 237 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde